Clinical Trial Update: CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating doxazosin for co-occurring PTSD and alcohol use disorders has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorders
• Posttraumatic Stress Disorder

Drugs mentioned

• Doxazosin (doxazosin)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Posttraumatic Stress Disorder, Alcohol Use Disorders | Phase 2 | Status: COMPLETED | Results posted: 2021-04-14